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Community-acquired methicillin-resistant Staphylococcus aureus is increasingly recog-
nized as an important pathogen causing skin and soft tissue infections. We report a case of
severe necrotizing pneumonia caused by community-acquired methicillin-resistant
S. aureus in a peripartum woman. This case illustrates that community-acquired
methicillin-resistant S. aureus must be considered as a potential pathogen in severe
community-acquired pneumonia.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Community-acquired methicillin-resistant Staphylococcus
aureus (CA-MRSA) often causes skin and soft-tissue infections.Elsevier Ltd. All rights reserved.
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), anne.dixon@uvm.eduWe recently observed a patient with severe necrotizing
pneumonia from CA-MRSA. Her hospital course was compli-
cated by severe acute respiratory distress syndrome (ARDS)
and ventilator-associated pneumonia. This case illustrates
that CA-MRSA should be considered in the differential of
severe community-acquired pneumonia (CAP).
Case report
A previously healthy 39-year-old woman, in her 38th week of
pregnancy, presented to the Emergency Department with
acute shortness of breath requiring emergent intubation.
She had a 2-week history of cough, shortness of breath,
fever, and sore throat. Three prior pregnancies had been
uncomplicated. She was transferred to our hospital for
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Figure 1 Chest X-ray shows bilateral airspace disease.
Table 1 Initial laboratory values.
Arterial blood gas
pH 7.24
PaCO2 20mmHg
PaO2 84mmHg
White blood cell count 10,000/ml with 9% bands
Lactic acid 2.2mmol/L
Brochoscopy cultures MRSA positive
Rapid Influenza A and B Negative
Blood cultures Negative
Figure 2 CT scan of the chest and abdomen showing left
pneumothorax with chest tubes, body wall emphysema, con-
solidation, effusion, and diffuse ground glass and cystic changes
throughout both, likely reflecting aggressive MRSA.
Staphylococcus aureus pneumonia 933further management, and gave birth to a healthy boy via
vacuum-assisted vaginal delivery in the intensive care unit
shortly after arrival. Chest X-ray showed bilateral airspace
disease (Figure 1). Her significant initial laboratory values
and culture data are recorded in Table 1. She was initially
treated with broad-spectrum antibiotics including vancomy-
cin (generic; Hospira Inc.; Lake Forest, IL).
She required high levels of support (100% oxygen for 8
days and 24 cm H2O of positive end expiratory pressure),
which was weaned per ARDSNet protocol.1 Chest CT scan
showed necrotizing cavitary pneumonia (Figure 2). She was
persistently febrile despite vancomycin and was thought to
be a nonresponder, so she was changed to linezolid (Zyvox;
Pfizer; New York, NY) and rifampin (generic; Ben Venue
Laboratories; Bedford, OH). Of note, while on linezolid and
rifampin, her linezolid trough level was at the lower limits of
detection (National Jewish Center for Immunology and
Respiratory Medicine; Denver, CO). She also developed a
ventilator-associated pneumonia and ultimately completed
a course of ceftazidime (Tazicef; Sandoz; GmbH Kundl,
Austria), daptomycin (Cubicin; Cubist Pharmaceuticals;
Lexington, MA), and ciprofloxacin (Cipro; Bayer Pharmaceu-
ticals Corp; West Haven, CT).
She remained ventilator-dependent for 35 days, but
eventually made a good recovery, and was discharged home
on hospital day 41.Discussion
MRSA is typically considered a hospital-acquired pathogen.
However, CA-MRSA is an emerging pathogen that can cause
severe infections in previously healthy people, as illustrated
by our report.2–7
CA-MRSA usually causes skin and soft tissue infections.
There have been outbreaks of MRSA skin and soft tissue
infections among athletes, the military, and prisoners.8 The
emerging destructive potential of CA-MRSA was illustrated
by a report between 1997 and 1999 of the deaths of four
previously healthy children in Minnesota and North Dakota
from CA-MRSA bacteremia, with various infected sources
including skin, pleural fluid, meninges, and a hip joint.3
MRSA usually involves the skin,9 often requires hospitaliza-
tion, and had a higher prevalence among persons less than 2
years old and blacks.2 CA-MRSA may also cause severe,
necrotizing pneumonia in previously healthy children and
adults. As in our patient, this often, but not always, occurs
after influenza or an influenza-like illness.7 Spread of MRSA
to close, familial contacts has been reported.5,6 CA-MRSA
pneumonia is reported to have high mortality.7
CA-MRSA is microbiologically distinct from hospital-
acquired methicillin-resistant S. aureus (HA-MRSA), with
virulence factors that contribute to the pathogenesis of
disease, such as the Panton–Valentine leukocidin genes.9,10
The Panton–Valentine leukocidin genes code for cytotoxin
production that causes tissue necrosis by forming pores in
cell membranes, especially in neutrophils.10 This may
contribute to its virulence.
CA-MRSA is typically more sensitive to antibiotics than
HA-MRSA. CA-MRSA often carries the staphylococcal cassette
chromosome mec-type IV element, which confers resistance
to b-lactams.11 Clindamycin has been effective for skin and
soft tissue infections, but there is emerging drug resis-
tance.11 For invasive CA-MRSA infections, including sepsis
and pneumonia, vancomycin and linezolid represent possible
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J.L. Martino et al.934therapeutic options.11 Linezolid has a theoretical advantage
in treating pneumonia as it achieves higher lung epithelial
lining fluid concentration compared to vancomycin.12,13 Our
patient was initially treated with vancomycin, then
switched to linezolid with rifampin (for synergy) because
of continued fevers.14 This may have lowered the linezolid
level15: rifampin stimulates P-glycoprotein expression, a
protein which actively transports drugs and metabolites out
of cells, and may lower the linezolid level.16 The most
recent recommendations by the Infectious Diseases Society
of America/American Thoracic Society on the management
of CAP in adults recommends vancomycin or linezolid for
CA-MRSA, though the most effective therapy has not yet
been defined.17
Traditionally, pneumonia during pregnancy has caused
significant maternal morbidity.18 However, outcomes have
improved with prompt diagnosis and treatment. Pregnant
women are not at increased risk of pneumonia, but
physiologic changes that occur during pregnancy may
complicate their presentation.
This is a report of CA-MRSA causing severe, necrotizing
pneumonia in a peripartum female. This case highlights the
importance of considering MRSA as a cause of community-
acquired infection in otherwise healthy people who present
with severe pneumonia, especially if preceded by influenza
or an influenza-like illness. Optimal therapy remains to be
defined.
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